News

GeneFirst Ltd collaborates with Novosanis

Novosanis, a spin-off of the University of Antwerp, and DDL Diagnostic Laboratory investigated the detection of human papillomavirus (HPV) in first-void urine.

Novosanis, a spin-off of the University of Antwerp, and DDL Diagnostic Laboratory investigated the detection of human papillomavirus (HPV) in first-void urine.

The European Commission granted a “Seal of Excellence” to Novosanis’ project proposal UROSCREEN on the use of Colli-Pee in cervical screening programs.

The European Commission granted a “Seal of Excellence” to Novosanis’ project proposal UROSCREEN on the use of Colli-Pee in cervical screening programs.

De Europese Commissie kende een “Seal of Excellence” toe aan het projectvoorstel UROSCREEN van Novosanis, gericht op het gebruik van Colli-Pee in bevolkingsonderzoek naar...

ANTWERP. POWERED BY CREATIVES. unites award-winning designers during their annual exposition . Novosanis and Voxdale were invited to showcase their innovative health care designs: Colli-Pee...

ANTWERP. POWERED BY CREATIVES. unites award-winning designers during their annual exposition. Novosanis and Voxdale were invited to showcase their innovative designs in regard to health...

Novosanis is proud to receive funding from the European Commission (Horizon 2020). The grant allows exploring strategies to successfully launch the Colli-Pee™ device to specifically reach...

Colli-Pee TM , a first void urine collection device, developed by Novosanis has received the IWT Innovation Award in the category “major social relevance”. Novosanis is very honored with...

Novosanis proudly presents its recently CE-labelled Colli-Pee device which is now ready for the market.

In this month's edition of the Flemish magazine "Ondernemers" (Entrepreneurs) by Voka, our CEO Vanessa Vankerckhoven proudly presents our 2 products Colli-Pee & VAX-ID.